Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Indiplon. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 known ✓ | P14867 | 1/20 | 0.48 |
| ▸ | CDKN1A | P38936 | 1/20 | 0.61 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.48 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.48 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.48 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.48 |
| ▸ | AOX1 | Q06278 | 1/20 | 0.48 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.48 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.43 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.43 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.43 |
| ▸ | PIM1 | P11309 | 4/20 | 0.41 |
| ▸ | MAPK13 | O15264 | 2/20 | 0.41 |
| ▸ | GSK3A | P49840 | 3/20 | 0.40 |
| ▸ | EPHA2 | P29317 | 1/20 | 0.40 |
| ▸ | AKT1 | P31749 | 1/20 | 0.40 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Indiplon SCHEMBL30292630 | 1.00 | CDKN1A (0.61) | CDKN1ATLR8KDM4EGABRA1GABRG2 | |
| Indiplon SCHEMBL3714581 | 1.00 | CDKN1A (0.61) | CDKN1ATLR8KDM4EGABRA1GABRG2 | |
| Indiplon SCHEMBL4807177 | 0.99 | CDKN1A (0.60) | CDKN1ATLR8KDM4EGABRA1GABRG2 | |
| SCHEMBL5819907 | 0.91 | CDKN1A (0.61) | CDKN1ATLR8KDM4EGABRA1GABRG2 | |
| SCHEMBL5809393 | 0.90 | CDKN1A (0.64) | CDKN1ATLR8KDM4EGABRA1GABRG2 | |
| SCHEMBL3155505 | 0.89 | CDKN1A (0.68) | CDKN1ATLR8KDM4EGABRA1GABRG2 | |
| SCHEMBL6071510 | 0.88 | CDKN1A (0.60) | CDKN1ATLR8KDM4EGABRA1GABRG2 | |
| SCHEMBL5798184 | 0.88 | CDKN1A (0.56) | CDKN1ATLR8KDM4EGABRA1GABRG2 | |
| SCHEMBL1874348 | 0.87 | CDKN1A (0.59) | CDKN1ATLR8KDM4EGABRA1GABRG2 | |
| Indiplon SCHEMBL17161278 | 0.87 | KDM4E (0.72) | CDKN1ATLR8KDM4EGABRA1GABRG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 3144 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12624037-B2 | Method of treating agitation, aggressive behavior, and impulse control disorder | INTRA-CELLULAR THERAPIES, INC. (US) | 2026-05-12 | — | — | US | claimed |
| US-12624036-B2 | Method of treating post-traumatic stress disorder | INTRA-CELLULAR THERAPIES, INC. (US) | 2026-05-12 | — | — | US | claimed |
| EP-3706762-B1 | N4-HYDROXYCYTIDINE DERIVATIVE AND ANTI-VIRAL USES RELATED THERETO | UNIV EMORY (US) | 2024-10-16 | — | — | EP | claimed |
| WO-2024150170-A1 | PIROMELATINE FOR TREATING PARASOMNIAS ASSOCIATED WITH LOSS OF REM SLEEP ATONIA | NEURIM PHARMACEUTICALS (1991) LTD. (IL) | 2024-07-18 | — | — | WO | claimed |
| US-20240238250-A1 | METHOD OF USING PIROMELATINE FOR TREATING PARASOMNIAS ASSOCIATED WITH LOSS OF REM SLEEP ATONIA | NEURIM PHARMACEUTICALS (1991) LTD. (IL) | 2024-07-18 | — | — | US | claimed |
| CN-110891562-B | Lithium salts of N-substituted glycine compounds and uses thereof | 心悦生医股份有限公司 | 2024-07-16 | — | — | CN | claimed |
| CN-118063466-A | 5-Cyano pyrazolo [1,5-a ] pyrimidine compound and synthetic method thereof | 皖西学院 | 2024-05-24 | — | — | CN | claimed |
| US-20220273600-A1 | LITHIUM SALTS OF N-SUBSTITUTED GLYCINE COMPOUNDS AND USES THEREOF | SYNEURX INTERNATIONAL (TAIWAN) CORP. (TW) | 2022-09-01 | — | — | US | claimed |
| WO-2022086835-A1 | COMBINATION PRODUCTS TO MITIGATE THE RISK OF NON-BENZODIAZEPINE BENZODIAZEPINE AGONIST ADVERSE REACTION AND OVERDOSE | PRESTI MICHAEL (US) | 2022-04-28 | — | — | WO | claimed |
| US-20220117916-A1 | Combination Products to Mitigate the Risk of Non-Benzodiazepine Benzodiazepine Agonist Adverse Reaction and Overdose | SAFERX PHARMACEUTICALS LLC (US) | 2022-04-21 | — | — | US | claimed |
| WO-2004039361-A1 | PULSATILE RELEASE COMPOSITIONS OF MILNACIPRAN | COLLEGIUM PHARMACEUTICAL, INC. (US) | 2004-05-13 | — | — | WO | claimed |
| WO-2004039320-A2 | STEREOISOMERS OF p-HYDROXY-MILNACIPRAN, AND METHODS OF USE THEREOF | COLLEGIUM PHARMACEUTICAL, INC. (US) | 2004-05-13 | — | — | WO | claimed |
| WO-2004037190-A2 | MODIFIED RELEASE COMPOSITIONS OF MILNACIPRAN | COLLEGIUM PHARMACEUTICAL, INC. (US) | 2004-05-06 | — | — | WO | claimed |
| WO-2004035021-A2 | BUCCAL POLAR AND NON-POLAR SPRAY OR CAPSULE CONTAINING DRUGS FOR TREATING DISORDERS OF THE CENTRAL NERVOUS SYSTEM | NOVADEL PHARMA INC. (US) | 2004-04-29 | — | — | WO | claimed |
| US-20030165566-A1 | Sedative non-benzodiazepine formulations | BIOVAIL LABORATORIES INTERNATIONAL SRL (BB) | 2003-09-04 | — | — | US | claimed |
| WO-2003059349-A1 | SEDATIVE NON-BENZODIAZEPINE FORMULATIONS | BIOVAIL LABORATORIES INC. (BB) | 2003-07-24 | — | — | WO | claimed |
| EP-1206248-B1 | CONTROLLED-RELEASE SEDATIVE-HYPNOTIC COMPOSITIONS AND METHODS RELATED THERETO | NEUROCRINE BIOSCIENCES INC (US) | 2003-06-04 | — | — | EP | claimed |
| US-20030077227-A1 | Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the central nervous system | NOVADEL PHARMA INC. | 2003-04-24 | — | — | US | claimed |
| EP-1208102-B1 | SYNTHESIS OF A SUBSTITUTED PYRAZOLOPYRIMIDINE | NEUROCRINE BIOSCIENCES INC (US) | 2003-03-26 | — | — | EP | claimed |
| US-20030004346-A1 | Synthesis of substituted pyrazolopyrimidines | NEUROCRINE BIOSCIENCES, INC. (US) | 2003-01-02 | — | — | US | claimed |